Research and Development

Vice president of Market Access, Health Policy & Medical Affairs at Sanofi Pasteur MSD Andrea Rappagliosi has been appointed president …

Boehringer Ingelheim has entered a five-year tie-up with a UK biotech company which specialises in helping research into personalised medicines. …

The former managing partner for US health at Hall & Partners has joined the consultancy firm Insight Health US as …

Eisai’s investigational oncology treatment farletuzumab has failed to reach its primary endpoint in a late-stage trial. Farletuzumab (MORAb-003) did not …

Pharma services company Clinigen Global Access Programs (Clinigen GAP) has appointed Dominic Atkins as global business development director. In this …

Barbara Jaszewski, has been appointed vice president of global pricing and market access at Lundbeck. She will be in charge …

Pharma supplier firm Cherwell Laboratories has announced the appointment of Abdulmajeed Raji as microbiology product specialist. Prior to joining Cherwell, …

Vaccines biotech firm Hookipa Biotech AG has appointed two new members to its management team. Thomas Monath (pictured) joins as …

Private biotech company MacroGenics has licenced its bi-specific antibody platform technology to Gilead Sciences for products aimed at four unnamed …

Healthcare services group MAPI has named James Karis as its chief executive. MAPI looks to Karis to consolidate its success …

Boehringer Ingelheim has handed back one of Eli Lilly’s investigational diabetes drugs as a result of ‘independent strategic portfolio considerations’. …

Novo Nordisk has announced that Curtis Oltmans has been promoted to corporate vice president and general counsel, Legal and Quality …

You’ve spent months building a marketing excellence training curriculum which has been prioritised by marketing leadership as a critically important …

David Cook has been appointed chief financial officer (CFO) of drug development firm Biotie Therapies and will become a member …

The world’s largest pharma companies will be under greater pressure to merge with or purchase other firms over the next …